WHEAT RIDGE, Colo., Nov. 3 /PRNewswire-FirstCall/ -- GeneThera, Inc. (Pink Sheets: GTHR), As a service and responsibility to our shareholders, GeneThera is publicly outlining our strategy for the future of the company. GeneThera is making a pivotal shift from a Research and Development organization into a product marketing and revenue generating entity.
The company strategy that we maintained from inception to our recent reverse split (July, 2008) had been one of research only. We focused all our energies, talent, and resources to the incubation and growth of new ideas in the realm of genetically engineered disease detection and vaccination. We feel that with recent announcements the company is positioned to move from a developmental stage to a product oriented stage
RECENT DEVELOPMENTS
Our recent developments include the progress we are making in regards to our Johne's Disease validation trials scheduled to begin in collaboration with the Universidad National Autonoma de Mexico, a prominent state university in Mexico City. Our joint venture with Nutricion Avanzada, (the joint venture created a new company Applied Genetics. Applied Genetics is the marketing arm of GeneThera for the Mexican marketing of our Johne's Disease testing service and subsequent Vaccine, (which is currently under development) has been in contact with several major ranchers throughout Mexico, and the overwhelming response from the ranchers has been an outcry for help in detecting and eliminating Johne's Disease which is running rampant in their herds. Government approval and recommendation is expected to occur quickly once the validation trials are complete. The validation trials should be complete within 3-4 months from start. We will be conducting paid testing on a limited basis during the validation trials.
The recent signing of our agreement with STC.UNM (the technology
development arm of The University of New Mexico) for the genetic vaccine
they have dev
'/>"/>
| SOURCE GeneThera, Inc. Copyright©2008 PR Newswire. All rights reserved |